Cryoport Q3 net loss widens 56% to $10.85 million; Q3 revenue rises 14% to $50.22 million

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Cryoport’s third-quarter 2026 net loss widened 56% year-over-year to $10.85 million. * Revenue rose 14% year-over-year to $50.22 million, including Life Sciences Services revenue of $28.56 million, up 18%. * The business supported 788 clinical trials worldwide and 23 commercially approved cell and gene therapies at September 30, 2026. * Full-year 2026 revenue guidance increased to a range of $197 million to $199 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryoport Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051605PR_NEWS_USPR_____LA90523) on November 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.